TELIX: Prostate Imaging Program (illumetTM) : Commercial and Regulatory Update
TLX591-CDx (68Ga-PSMA) for the imaging of prostate cancer with positron emission tomography (PET). Branded as illumetTM in the US market.
top of page
THE ROLE OF BOARD MEMBERS
-
Board members are entrepreneurial executives with extensive experience in asset management, startups/SMEs and global corporations
-
Board controls investment, budget, nomination, compensation, audit, and guarantees alignment of interests
-
Board is regulated by an organization charter
-
Board operates its own internal processes and procedures based on EVCA professional standards
THE ROLE OF BOARD MEMBERS
-
Board members are entrepreneurial executives with extensive experience in asset management, startups/SMEs and global corporations
-
Board controls investment, budget, nomination, compensation, audit, and guarantees alignment of interests
-
Board is regulated by an organization charter
-
Board operates its own internal processes and procedures based on EVCA professional standards
Search
TELIX: Fractionated Prostate Cancer Therapy Data Published, Significant Treatment Benefit
Date: 26th April, 2019 Program relevance: TLX591 (Prostate Therapy), TLX591-CDx (Prostate Imaging) Synopsis: The development of TLX591 is...
bottom of page